Jasper Therapeutics (JSPR) Cash & Equivalents (2019 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Cash & Equivalents of $28.7 million for Q4 2025, down 59.95% year-over-year from $71.6 million in Q4 2024, and down 43.63% quarter-over-quarter from $50.9 million in Q3 2025.
Jasper Therapeutics (JSPR) Cash & Equivalents (2019 - 2025) Analysis & Trends
Jasper Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $28.7 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 59.95% year-over-year to $28.7 million; the TTM figure through Dec 2025 stood at $28.7 million (down 59.95% YoY), while the FY2025 annual figure was $28.7 million, down 59.95% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $28.7 million, down from $50.9 million in the prior quarter.
- The five-year high for Cash & Equivalents was $129.4 million in Q1 2023, with the low at $309730.0 in Q2 2021.
- The 5-year median for Cash & Equivalents is $70.5 million (2022), against an average of $69.8 million.
- The sharpest annual moves came in 2021 and 2022: Cash & Equivalents plunged 66.12% in 2021, then surged 19534.52% in 2022.
- Jasper Therapeutics' Cash & Equivalents stood at $84.7 million in 2021, then tumbled by 54.84% to $38.2 million in 2022, then surged by 127.16% to $86.9 million in 2023, then declined by 17.55% to $71.6 million in 2024, then slumped by 59.95% to $28.7 million in 2025.
- Business Quant data shows JSPR's Cash & Equivalents at $28.7 million in Q4 2025, $50.9 million in Q3 2025, and $39.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | 7.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.69 Mn |
| Sep 30, 2025 | 50.90 Mn |
| Jun 30, 2025 | 39.50 Mn |
| Mar 31, 2025 | 48.80 Mn |
| Dec 31, 2024 | 71.64 Mn |
| Sep 30, 2024 | 92.50 Mn |
| Jun 30, 2024 | 106.82 Mn |
| Mar 31, 2024 | 118.48 Mn |
| Dec 31, 2023 | 86.89 Mn |
| Sep 30, 2023 | 102.87 Mn |
| Jun 30, 2023 | 115.81 Mn |
| Mar 31, 2023 | 129.40 Mn |
| Dec 31, 2022 | 38.25 Mn |
| Sep 30, 2022 | 49.95 Mn |
| Jun 30, 2022 | 60.81 Mn |
| Mar 31, 2022 | 69.40 Mn |
| Dec 31, 2021 | 84.70 Mn |
| Sep 30, 2021 | 99.91 Mn |
| Jun 30, 2021 | 309,730.00 |
| Mar 31, 2021 | 590,605.00 |